Samsara BioCapital’s ACELYRIN SLRN Stock Holding History

Samsara BioCapital’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,523,022	Closed	-$6.23M	–	38
2025 Q1	$6.23M	Hold	2,523,022	–	–	1.11%	17
2024 Q4	$7.92M	Hold	2,523,022	–	–	1.09%	17
2024 Q3	$12.4M	Hold	2,523,022	–	–	2.39%	12
2024 Q2	$11.1M	Hold	2,523,022	–	–	2.33%	13
2024 Q1	$17M	Hold	2,523,022	–	–	2.63%	9
2023 Q4	$18.8M	Buy	2,523,022 +141,443	+6%	+$1.21M	2.93%	9
2023 Q3	$24.2M	Buy	2,381,579 +125,557	+6%	+$2.67M	7.41%	4
2023 Q2	$47.2M	Buy	+2,256,022	New	+$46.1M	8.28%	3

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Samsara BioCapital's SLRN Position: Q2 2025 in Review

Samsara BioCapital sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 2,523,022 shares — an estimated $6.23M sold.

Samsara BioCapital first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $47.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Samsara BioCapital reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Samsara BioCapital sold 2,523,022 ACELYRIN shares in Q2 2025, an estimated $6.23M.
Samsara BioCapital first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Samsara BioCapital's ACELYRIN position peaked at $47.2M in Q2 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Samsara BioCapital's 13F filing for Q2 2025, filed 14 Aug 2025.